Related Experiment Video

Updated: Jun 6, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines

Sandra E Talbird1, Afisi S Ismaila, Thomas N Taylor

  • 1RTI Health Solutions, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA. stalbird@rti.org

Vaccine
|November 16, 2010
PubMed

Insights

The 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) offers greater clinical benefits than the 7-valent pneumococcal conjugate vaccine (PCV-7) in Canada. PHiD-CV significantly reduces disease cases and deaths, particularly acute otitis media.

Area of Science:

  • Pediatric Infectious Diseases
  • Vaccinology
  • Public Health Modeling

Background:

  • Pneumococcal conjugate vaccines (PCVs) are crucial for preventing pneumococcal diseases.
  • Evaluating new vaccine formulations like the 10-valent PHiD-CV is essential for public health decision-making.
  • Understanding the comparative clinical impact of different PCVs is vital for optimizing vaccination strategies.

Purpose of the Study:

  • To estimate the clinical impact of routine infant vaccination with PHiD-CV compared to PCV-7 and no vaccination in Canada.
  • To utilize a novel steady-state, population-based model to simulate vaccination effects.
  • To quantify the reduction in disease incidence and mortality associated with PHiD-CV.

Main Methods:

  • Development of a deterministic, compartmental model simulating a steady-state population of 32.9 million.
  • Incorporation of herd and replacement effects across all age groups for a 1-year period.
  • Calculation of annual clinical outcomes for three vaccination strategies: PHiD-CV, PCV-7, and no vaccination.

Main Results:

  • PHiD-CV demonstrated a greater impact in preventing disease cases and deaths compared to PCV-7 and no vaccination.
  • PHiD-CV vaccination was estimated to prevent an additional 155,757 cases of acute otitis media (AOM) compared to PCV-7.
  • The model estimated PHiD-CV prevented an additional 10 invasive disease cases, 416 pneumonia cases, 8943 myringotomy procedures, and 6 deaths.

Conclusions:

  • Routine infant vaccination with PHiD-CV provides significant clinical benefits over PCV-7 in Canada.
  • The largest incremental impact of PHiD-CV was observed in the prevention of acute otitis media (AOM).
  • Model validation against existing data for PCV-7 suggests reliability in estimating vaccine impact.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...